Explore our pipeline
We've played a role in delivering 14 new cancer treatments for patients. Explore our clinical and preclinical assets currently in development.
The licensed antibody selectively binds to a cell surface-presented protein that is over-expressed in certain types of cancer including colorectal cancer. The antibody was originally developed by Cancer Research UK.
Glycart will use its proprietary GlycoMAB technology to enhance the in vivo efficacy of the antibody. A research collaboration between CRT, Glycart and the University of Oxford has been established to investigate the potential efficacy of the glyco-engineered antibody in pre-clinical studies.
Dr Phil L’Huillier, CRT’s director of business management, said: “This is a significant step forward in the development of this technology as a therapeutic agent. We’re very pleased that Glycart is taking this exciting antibody forward and we look forward to the development of a therapeutic that will help treat bowel cancer more efficiently.”
Notes to editors
University of Oxford
The University of Oxford is ranked third in the world for biomedicine (Times Higher Education Supplement). Oxford’s Medical Sciences Division is one of the largest biomedical research centres in Europe and accounts for a third of the University’s income and expenditure and two thirds of external research income. A strong research programme in cancer is supported by a new Institute for Cancer Medicine, to open in 2008, opposite the city's new £100m cancer hospital. www.ox.ac.uk
